Novavax: Why I believe this is a very good investment opportunity now (NVAX)

Some information about the company: they develop excellent protein-based vaccines, the formula they have produces the safest and most efficient vaccine in the world. The only other possible way to increase the efficacy is to use a live vaccine. However live vaccines carry the risk of virus in the vaccine mutating back to pathological form after several replication cycles. And immunocompromised patients can’t take them. That makes protein-based vaccines one of the best possible types. Hepatitis B and Human Papilloma Virus vaccines are protein bases vaccines routinely administered in teenagers. Hepatitis B is given to newborn kids. Now they have developed a protein-based vaccine for Covid and it has the highest efficacy among any approved Covid vaccine anywhere. It is also the safest vaccine. It is currently being tested on 6 months old infants. They have advanced purchase agreements as follow: US government has provided them 1.75 Billion dollars in return for 100 million doses when approved Australia: 51 million Canada: 52 million Europe: 100 million UK 60 million New Zeland 10.71 million World Health Organization: 300 million doses South Korea and Japan also have production and purchase agreements. This means all these countries will have to buy their vaccine even if they don’t need them. India has approved the vaccine and plans to use this vaccine for kids. The expected conservative revenue from all these contracts is more than 7 billion. And this entity has the option to purchase more. The current market cap of the company is less than the expected revenue for the year 2022, making it an excellent investment choice. Also, it will be a vaccine of choice for the pediatric population. They also have a Flu vaccine completed trial which is as good or even better than currently used flu shots. They have a plant to introduce a combined shot. Additionally, they are also working on the RSV vaccine. And their malaria vaccine Is the only vaccine to meet WHO standards for efficacy and safety. The research for the malaria vaccine has been going on for decades. This speaks for the technology of the company.

Mindcantgraspme

Jan 26, 2022

-34.47%

Change % Since Posting

-29.25

Change Since Posting

84.86

Price When Posted

NVAX

Novavax, Inc.

55.61

6.46 13.72%

Current Price

Novavax: Why I believe this is a very good investment opportunity now (NVAX)

bullish

Some information about the company: they develop excellent protein-based vaccines, the formula they have produces the safest and most efficient vaccine in the world. The only other possible way to increase the efficacy is to use a live vaccine. However live vaccines carry the risk of virus in the vaccine mutating back to pathological form after several replication cycles. And immunocompromised patients can't take them. That makes protein-based vaccines one of the best possible types. Hepatitis B and Human Papilloma Virus vaccines are protein bases vaccines routinely administered in teenagers. Hepatitis B is given to newborn kids.

Now they have developed a protein-based vaccine for Covid and it has the highest efficacy among any approved Covid vaccine anywhere. It is also the safest vaccine. It is currently being tested on 6 months old infants. They have advanced purchase agreements as follow:

US government has provided them 1.75 Billion dollars in return for 100 million doses when approved

Australia: 51 million

Canada: 52 million

Europe: 100 million

UK 60 million

New Zeland 10.71 million

World Health Organization: 300 million doses

South Korea and Japan also have production and purchase agreements.

This means all these countries will have to buy their vaccine even if they don't need them.

India has approved the vaccine and plans to use this vaccine for kids.

The expected conservative revenue from all these contracts is more than 7 billion. And this entity has the option to purchase more. The current market cap of the company is less than the expected revenue for the year 2022, making it an excellent investment choice.

Also, it will be a vaccine of choice for the pediatric population. They also have a Flu vaccine completed trial which is as good or even better than currently used flu shots. They have a plant to introduce a combined shot. Additionally, they are also working on the RSV vaccine. And their malaria vaccine Is the only vaccine to meet WHO standards for efficacy and safety. The research for the malaria vaccine has been going on for decades. This speaks for the technology of the company.